3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
8
Lymphoma, Follicular
8
Lymphoma
7
Lymphoma, Large B-Cell, Diffuse
6
Lymphoma, B-Cell, Marginal Zone
5
Recurrence
4
Lymphoma, Mantle-Cell
4
Myeloproliferative Disorders
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hereditary Sensory and Autonomic Neuropathies
1
B-Cell Malignancies
1
Interventions
duvelisib
3
parsaclisib
1
obinutuzumab
1
liposomal doxorubicin
1
chiauranib
1
Taxes
1
Rituximab
1
Panobinostat
1
Paclitaxel
1
Lomustine
1
Irinotecan
1
Gemcitabine
1
Everolimus
1
Doxorubicin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
parsaclisib
×
Lymphoid
×
Clear all
NCT03126019
2025-03-14
CITADEL-203
Incyte Corporation
Phase 2
Completed
126 enrolled
15 charts